country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99620

Copy Link Print Information

Firivumab

(Synonyms: CT-P22; CT120)

Customer Review

Based on 1 Customer Validation

Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice.

For research use only. We do not sell to patients.

Purity: 95.00%
CAS No.: 1443004-15-6
Molecular Weight:145.62 kDa

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Firivumab Chemical Structure

CAS No.: 1443004-15-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Accession
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Virus

IC₅₀ & Target

influenza A virus hemagglutinin HA

In Vivo

Firivumab (CT-P22; CT120; 7.5-30 mg/kg; IP; Twenty-four hours post-infection) shows 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group^[1].
CT-P27 (adding 7.5 mg/kg Firivumab and 7.5 mg/kg CT149) shows full protection in A/California/04/09 (H1N1)-treated mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2)^[1]
Dosage:

7.5, 15, 30 mg/kg
Administration:

IP; Twenty-four hours post-infection
Result:

Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group.
Could not protect mice from H3N2 infection.

Accession

C3W5S1

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

Application

ELISA, FACS, Functional assay

Chemical Information

CAS No. 1443004-15-6
Appearance Liquid
Molecular Weight 145.62 kDa
Color Colorless to light yellow
SMILES

[Firivumab]
Synonyms

CT-P22; CT120
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (260 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Kye Sook Yi, et al. Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. PLoS One. 2020 Jul 29;15(7):e0236172. [Content Brief]

[2]. John H Beigel, et al. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038463. [Content Brief]

[3]. Seung Suh Hong, et al. Composition comprising at least two influenza a virus-neutralizing-binding molecules. EP3011968A1.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

100 mg

Get Quote In-stock

Amount: USD 0.00

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Accession
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Firivumab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

Antibody Inhibitor Library

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Firivumab Related Classifications

HY-P99620 Related Classifications